ElectroCore

ElectroCore

ElectroCore

Developing therapies that directly, and non-invasively, target nerve signal imbalances to restore normal neurological function.
Type
B2b
Founded
2005
Raised
$85.5M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$34,000,000
Venture capital (Series B) - 2017
Merck Global Health Innovation Fund Core Ventures Group Knoll Capital Management +2
$1,500,000
Debt financing - 2016
Team Size
10+
Employees
PE HUB

U.S. medical device firm electroCore IPO price set at $15 per share: Reuters

Health